Kornimate/medical-research-clean huggingface dataset:
vibration training and muscle strength development

Conditions: Muscle Strength; Disabilities of the Arm, Shoulder and Hand

Summary: introduction: vibration has been used to enhance muscle strength development during resistance training. aim: to assess the effect of adding vibration to a regular resistance training program, using free weights, on muscle strength and everyday functioning of upper limbs in untrained adults methods: 60 healthy untrained adults, 30-65 yrs, will divide into two groups: experiment and control. training program will include 24 sessions, over a course of 8 weeks. the experiment group will use a 1 kg vibrating weights and the control group will use a standard 1 kg free weights. every session will include 10-15 min of 3-5 standard resistant exercises for upper limbs. each subject will perform an isokinetic evaluation of muscular performance, for upper limbs, in 3 occasions: before starting the program, immediately after completing the 8-weeks training program and 4 weeks afterwards, to check the chronic effect of each training regime. each subject will complete a dash (disabilities of the arm, shoulder and hand) questionnaire at 4 occasions- as mentioned above and one more time, when completing the first 4 weeks of the training program, to reject any development of negative effects of the training program, such as pain or inflammation of the joints .


Eligibility criteria:
inclusion criteria: * healthy adults, ages 30-65 * not participating in resistance training for upper limbs regularly exclusion criteria: * unbalanced hypertension * cardiovascular disfunction or disease * pain and or/ inflammation of the neck, shoulders and arms * pregnant women
functional characterization of thrombopoietin/cmpl receptor mutations in myeloproliferative neoplasia

Conditions: Myeloproliferative Disorder

Summary: the mpl gene is implicated in two groups of hematological pathologies: congenital amegakaryocytic thrombocytopenia (camt) and phi negative myeloproliferative neoplasia (mpn). fifty germline mutations have been identified in camt, yet only a dozen activating mutations have been described in mpn. most are somatic, distributed mainly in the transmembrane (tm) and juxtamembrane (jm) domains. however, a few rare germline mutations located in the extracellular domain (ecd) have also been reported: k39n, r102p and p106l. next generation sequencing technology has been used to study the complete mpl gene, identifying numerous variants, most of unknown significance. the study investigators have a series comprising 41 variants of unknown significance, whose allelic frequencies suggest a germline origin for 80% of them. their distribution within the mpl gene is similar to that of inactivating mutations, except that they were discovered in the context of suspected myeloproliferative disease. characterizing the activity of these variants would confirm the diagnosis of mpn, opening the door to specific treatment (cytoreductive, jak2 inhibitor or interferon). it also has an important prognostic value, particularly in the case of mpn, for which life expectancy varies from 5 to 7 years, with terminal progression to acute myeloid leukemia (aml in 15 to 20% of cases) or bone marrow failure. using a battery of functional assays, this study aims to characterize these variants.


Eligibility criteria:
inclusion criteria: • patient with suspected mpn exclusion criteria: • patient with variant of cmpl already described in the literature.

Keywords: leukemia neoplasm polymorphism thrombocythemia thrombopoietin receptor,
linked color imaging vs. white light for colorectal dysplasia in ulcerative colitis

Conditions: Ulcerative Colitis

Summary: the purpose of the study is to determine whether a new colonoscopic viewing technique called linked color imaging(lci) helps endoscopists detect more dysplasia lesions in ulcerative colitis patients than conventional colonoscopy using white light alone.

patients with longstanding ibd have increased risk of colorectal cancer (crc) compared to the general population. the association between duration of the disease and development of crc is the rationale for endoscopic surveillance. colonoscopic surveillance of ulcerative colitis patients has been shown to reduce the risk of colorectal cancer and allow detection at an earlier stage, but even with meticulous examination, some precancerous lesions or cancers are missed. the newly developed lci system (fujifilm co.) creates clear and bright endoscopic images by using short-wavelength narrow-band laser light combined with white laser light on the basis of bli technology. lci makes red areas appear redder and white areas appear whiter. thus, it is easier to recognize a slight difference in color of the mucosa. this is a study to determine if using linked color imaging (lci) of the colon, rather than the usual white light on the colon, will improve the detection of more dysplasia lesions in ulcerative colitis.

Eligibility criteria:
inclusion criteria:patients with ulcerative colitis who meet surveillance criteria exclusion criteria:pregnant patients,unable or unwilling to give informed consent,patients with severe active colitis who would be unsafe to endoscope

Keywords: ulcerative colitis colonoscopy dysplasia diagnosis
the effects of botulinum toxin on oral aperture in patients with scleroderma

Conditions: Scleroderma

Summary: this study will evaluate the use of botulinum toxin for microstomia (also known as reduced oral aperture) in scleroderma patients. botox is a neurotoxin that functions as a paralytic by preventing the release of acetylcholine to inhibit muscle contracture and decrease fibrosis by decreasing differentiation of fibroblasts to myofibroblasts, decreasing expression of collagen, and increasing expression of matrix metalloproteinase1-3. the study will include three arms: the temporomandibular joint (tmj) group who will receive injections of botox to the masseter, the perioral group who will receive injections of botox around the lips, and a control group who will receive no treatment for roa. outcome measurements will include measurement of oral aperture size through measurement inter-labial distance and between the upper and lower lips and the inter-incisal distance, patient satisfaction via a skindex16 survey, mouth disability via the mouth handicap in systemic sclerosis scale (mhiss), and patient and physician satisfaction using the visual analogic scale (vas). the maximum number of subjects to be consented for this study is 30. the study is expected to last four months per subject from time of consent to last clinical evaluation. conditions that may result in a subject exiting the study prior to completion date include non-compliance, withdrawal of consent, or safety concerns such as adverse events as a result of treatment.


Eligibility criteria:
inclusion criteria: 1. ddiagnosis of scleroderma (defined by the 2013 classification criteria for systemic sclerosis4,5)23,24 ) who also have microstomia (reduced oral aperture), defined as an inter-incisal distance less than 50 mm 6-7)m13,14 . 2. male and female subjects. 3. english and non-english speakers. 4. subjects aged 18 years old to 65 years old will be considered exclusion criteria 1. patients under 18 years old will be excluded. 2. patients with a known history of a hypersensitivity to any botox formulation or to any of the components in the formulation, 3. active skin infection at the proposed injection site. 4. concomitant neuromuscular disorder. 5. pregnant or lactating. 6. missing incisors. 7. treatment with: cyclophosphamide, ultraviolet a-1 therapy, or topical calcitriol..
diet and aggression: reducing aggression among chronic psychiatric inpatients through dietary supplementation

Conditions: Psychiatric Hospitalization

Summary: the overall goal of this study is to investigate whether the daily administration of multivitamins, minerals and n-3 fatty acids will reduce aggression in long-term psychiatric inpatients and will thereby reduce costs of care.

aggressive incidents are highly prevalent among chronic psychiatric inpatients. previous studies have demonstrated the potential of multivitamin-, mineral-, and n-3 fatty acids (n-3fa) supplementation to reduce aggression in adolescent and forensic populations. to test the hypothesis that multivitamin-, mineral-, and n-3fa supplementation reduces aggression among chronic psychiatric inpatients, we designed a pragmatic, randomised, double-blind, placebo controlled, multicentre intervention study among psychiatric inpatients residing in long-stay psychiatric wards. during 6 months, one group receives 2 supplements daily from orthica: one containing vitamins and minerals (vitamins \[b1, b2, b3, b5, b6, b11, b12, c, d, e, beta carotene; calcium, iodine, copper, magnesium, selenium, iron, zinc, potassium, chrome, manganese\]) and one containing fish fatty acids (n-3fa: eicosapentaenic acid \[epa\] and docosahexaenic acid \[dha\]) and the other group receives 2 placebo capsules. the main study parameter is the number of aggressive incidents from baseline (t0) to endpoint (six months post baseline, t3). patients who wish to participate enter a 2-week run-in phase in which they take 2 placebo capsules daily. after positive evaluation of this run-in phase patients are randomized to the active or the control condition. participants will then start the daily use of 2 supplement capsules or 2 placebo capsules, which will continue for 6 months. at 3 time points (at baseline \[t0\] and at 2 and 6 months post-baseline \[t2 and t3\]), three questionnaires measuring feelings of aggression, quality of life, and psychiatric symptoms will be administered. also, at t0 and t3 (micro)nutrient status will be determined. finally, at 4 time points (t0, 2 weeks post baseline \[t1\], t2 and t3), nursing staff will report on observed levels of aggression and social dysfunction.

Eligibility criteria:
inclusion criteria: * residing at a facility for long-term psychiatric inpatient care * age 18 or over exclusion criteria: * pregnancy * breastfeeding * known contra-indication for using the supplements used in this study * expected discharge or transfer within the next 8 weeks * current use of dietary supplements and refusal to stop using these for the duration of the study * failure to complete run-in phase * contra-indication for the use of pork-gelatin

Keywords: nutrition aggression n-3 fatty acids psychiatry inpatients admitted >2 years
role of the orexin receptor system in stress, sleep and cocaine use

Conditions: Cocaine Use Disorder; Anxiety

Summary: the purpose of this study is to determine the effectiveness of a medication called suvorexant in reducing anxiety, improving sleep, and reducing cocaine cravings or cocaine use.

preclinical research has established important functions for the orexin system in mediating arousal/sleep, stress, and cue-induced reinstatement of drug taking (e.g., relapse). the role of stress/anxiety and drug cue reactivity in human drug relapse is well established, but to date, the role of the orexin system in modulating these phenomena has not been examined in humans with substance use disorders (e.g., cocaine). the goal of the present first-in-human study will be to examine the effects of an orexin antagonist (suvorexant) on interactions among stress/anxiety, sleep, and drug-cue reactivity. the study will utilize a battery of highly sensitive, drug-specific, laboratory measures of drug cue reactivity (a relapse risk model), and well-established metrics of stress/anxiety and sleep. the hypothesis is that antagonism of the orexin system will attenuate the link between (1) stress/anxiety and drug cue reactivity, and (2) sleep and drug cue reactivity. these results will elucidate a unique biochemical mechanism for understanding relapse, and provide a potential medication target for relapse prevention.

Eligibility criteria:
inclusion criteria: * meet current dsm-5 criteria for cocaine use disorder (cud) of at least moderate severity (≥4 symptoms) exclusion criteria: * current dsm-iv diagnosis of any psychoactive substance dependence other than cocaine, marijuana, or nicotine * have a dsm-iv axis i psychiatric disorder or neurological disease or disorder requiring ongoing treatment and/or making study participation unsafe * significant current suicidal or homicidal ideation * medical conditions contraindicating administration of suvorexant (e.g., severe pulmonary disease, severe cardiovascular disease or clinically abnormal eeg, severe liver or kidney disease, seizure disorder, or sleep disorder - particularly narcolepsy) * taking medications known to have significant drug interactions with the study medication(s) (e.g., mao inhibitors, anticonvulsants, haloperidol, phenothiazines, anesthetics, and all sedatives) * currently or recently (last 3 months) treated for substance use \[other than cocaine or nicotine\] or another psychiatric condition * conditions of probation or parole requiring reports of drug use to officers of the court; (8) impending incarceration * pregnant or nursing for female patients * inability to read, write, or speak english \[required for lab tasks and psychometric scales\] * unwillingness to sign a written informed consent form * subjects with alcohol use disorders or are drinking \> 7 alcoholic drinks per week. all subjects who are excluded will be given referral information to other local treatment programs.

Keywords: cocaine sleep anxiety craving addiction orexin cue reactivity suvorexant belsomra
an analysis of the efficacy of a pre-emptive multimodal pain regimen in reducing acute post-operative pain and narcotic pain medication requirements in spine surgery

Conditions: Pain, Postoperative; Spine Injuries and Disorders; Narcotic Use

Summary: the aim of this study is to investigate the hypothesis that multimodal pain regimen (consisting of acetaminophen, celecoxib, gabapentin, and oxycodone) administered pre-operatively before elective spine surgery significantly decreases acute pain post-operatively as well as decreasing requirements of post-op opioids for pain control in pacu as compared to patients undergoing elective spine surgery without a pre-operative pain regimen.


Eligibility criteria:
inclusion criteria: * undergoing elective spine surgery at nyu winthrop * age over 18 years exclusion criteria: * history of neuromuscular disorders * history of inflammatory arthropathies * history of spine metastases or active cancer in spine * medical history including any of the following: renal dysfunction, gastric ulcers, hepatic dysfunction, coagulopathic/bleeding disorders, prior adverse or allergic reactions to any of the medications in the study * age less than 18 years
safety and efficiency of γδ t cell against breast cancer

Conditions: Breast Cancer

Summary: in this study, effects of γδt cells on human breast cancer in combination with tumor reducing surgery, for example, cryosurgery going to be investigated.

breast tumor will be removed using tumor reducing surgery such as cryosurgery. pbmc of the patient will be separated from peripheral blood. after making them potential cancer killer γδ t cell, they will be infused to the patients as an immunotherapy treatment note: originally, our designed proposal was to use autologous pbmcs from cancer patients to ex vivo expand vγ9vδ2-t cells, and then perform adoptive transfer therapy. however, pbmcs of majority of cancer patients could not be effectively expanded, including cell number, cell purity and cell function could not meet the requirements of reinfusion. meanwhile, those patients could not tolerate 100ml of blood drawing for culture every 2 \~ 3 weeks. therefore, we submitted new clinical study application to the ethical committee of the fuda hospital affiliated with jinan university (guangzhou, pr. china) by changing the autologous protocol with the allogeneic protocol. after the allogeneic protocol was approved, we adapted allogeneic cells instead of autologous in our subsequentially clinical study.

Eligibility criteria:
inclusion criteria: age: 18-75 karnofsky performance status \>50 diagnosis with breast cancer based on histology or the current accepted radiological measures classification tumor,nodes,metastasis-classification(tnm) stage: ⅱ,ⅲ,ⅳ will receive cryosurgery, ire, surgery, gd t cells life expectancy: greater than 6 months ability to understand the study protocol and a willingness to sign a written informed consent document exclusion criteria: patients with other kinds of cancer history of coagulation disorders or anemia patients with heart disease insulin dependent diabetes thyroid disease

Keywords: immunotherapy, γδ t cell, breast cancer
effect of different size of patellar resurfacing on patellar crepitus of the one-stage bilateral total knee arthroplasty.

Conditions: Osteoarthritis (OA) of the Knee; OA Knee

Summary: the goal of this study is to compare the incidence of patella crepitation using different size of patella component in bilateral simultaneously total knee arthroplasty with patella resurfacing. the main question is does size of patella component effect the incidence of patella crepitus? in the control group, anatomically sized patella components were used, whereas the intervention group received 3 mm smaller, reduced-size patella components. participants were scheduled for follow up examination 2 weeks, 6 weeks, 6 months and 1 year for incidence of the patella crepitation and other outcomes.

for decades, total knee arthroplasty (tka) has been the treatment of choice for knee osteoarthritis, with posterior-stabilized (ps) systems showing excellent long-term outcomes. however, patellar crepitus is more common with ps tka systems because the cam and post mechanism can entrap fibrosynovial tissue within the intercondylar box, causing crepitus or clunking. patellar crepitus (pc) was defined as an audible grinding noise or palpable vibrations in the knee during active and passive range of motion, detected by the examiner's hand on the patient's patella and sometimes can be audible. this study was designed as a single-center, prospective randomized controlled trial comparing anatomical and reduced size of patella component in patients who underwent sequential bilateral tka with patella resurfacing under single anesthesia. all participants were blinded to their intervention. a total of 94 knees from 47 patients were randomly assigned to undergo tka with an anatomically sized patella component in one knee and reduced-size patella component in another knee or vice versa. crepitus, as a primary outcome, was assessed at 2, 6, 24 and 48 weeks follow-up using a validated and standardized approach. crepitus was graded as: 0 (none), 1 (fine palpable), 2 (coarse palpable), and 3 (audible). secondary outcomes included anterior knee pain (akp), feller's patella score (fps), kujala score, knee society score (kss), range of motion (rom), radiographic findings, and complications. akp was measured using a 10-cm visual analog scale (vas) in 1-cm increments. knee rom was measured with a goniometer. radiographic parameters were measured at 6 months postoperatively.

Eligibility criteria:
inclusion criteria: * age between 50 and 80 years. * american society of anesthesiologists (asa) classification 1 or 2. * diagnosed with primary knee osteoarthritis and requires bilateral total knee arthroplasty with patellar resurfacing. * participants can understand and consent to participate in the research project exclusion criteria: * secondary knee osteoarthritis, * previous knee surgery or arthroscopic surgery * individuals who cannot undergo surgery due to underlying medical conditions. * bmi \> 40 kg/m2 * infection around the knee

Keywords: patella crepitation crepitus patella clunk
examination of focal therapies- mri-fusion, hifu, nanoknife and cryotherapy

Conditions: Prostate Cancer

Summary: the main objective of this study is to determine whether focal-driven therapies for diagnosis and treatment of prostate cancer are preferable over current clinical methods. different focal procedures will be examined, including magnetic resonance imaging (mri)-target biopsy, and focal treatment as high intensity focused ultrasound (hifu), cryoablation and nano-knife.

men who are scheduled to undergo a focal therapy will be given patient information sheet, which explains the study in lay terms. fully informed consent, written or verbal (by phone) will be sought and documented before collecting any research data. the following information will be collected for all patients: * demographic data: date of birth, age, gender, ethnicity, height, weight. * medical history: number and results of previous biopsies, previous protein specific antigen (psa) tests. for patients who have undergone or are scheduled to undergo mri-us fusion biopsy, the following information will be collected: * mri: mri protocol, mri results: suspected lesions, apparent diffusion coefficient (adc) values. * biopsy procedure details and results: duration and success of procedure, number of cores taken, pathological results, following treatment (if applicable). for patients who have undergone or are scheduled to undergo hifu or nano-knife or cryotherapy the following data will be collected: * procedure details. * evaluation of success: results of following psa test, mri and/or prostate biopsy. patients undergoing hifu, nano-knife or cryotherapy will also be asked to complete two questionnaires: ipss, a validated lower urinary tract symptom questionnaire, and iief, a validated erectile function questionnaire.

Eligibility criteria:
inclusion criteria: 1. men who have underwent, or are scheduled to undergo a focal therapy treatment at ramat aviv medical center or rabin medical center 2. age 18-90. exclusion criteria: none.

Keywords: mri-targeted prostate biopsy focal treatment
the effect of high-dose remifentanil on established capsaicin-induced hyperalgesia in human volunteers

Conditions: Hyperalgesia

Summary: treatment of chronic pain is a major clinical challenge since chronic pain is frequent and leads to deterioration of quality of life. an injury or wound can lead to long term changes in the nervous system that make the skin more sensitive at and near the injury; this is termed hyperalgesia and occurs through long term depotentiation (ltp), i.e., a change in the synaptic interaction between neurons. opioids are the gold standard for the symptomatic therapy of moderate to severe pain. now, in animal studies the investigators have discovered previously unrecognized effects of opioids. intradermal injection of capsaicin (injection of pepper extract into the skin) is an established pain model in humans. the investigators want to test the influence of remifentanil, an ultra-short acting opioid, on hyperalgesia observed after intradermal capsaicin in human volunteers in a double blind cross-over prospective active placebo controlled clinical trial.


Eligibility criteria:
inclusion criteria: * men or women, aged between 19 and 40 years * body mass index between 15th and 85th percentile * normal findings in the medical history and physical examination * drug free for 1 week prior to the study day exclusion criteria: * regular use of medication especially analgesics * abuse of alcoholic beverages, drug abuse * history of asthma * participation in a clinical trial in the 2 weeks preceding the study * symptoms of a clinically relevant illness in the 2 weeks before the first study day * resting systolic blood pressure \> 135 mmhg or diastolic blood pressure \> 85 mmhg * acute skin diseases like sunburn on the relevant areas or skin lesions * pregnancy or breast feeding * regular consumption of very spicy (capsaicin containing) food * allergy against any medication used in the study protocol

Keywords: capsaicin remifentanil hyperalgesia